Skip to content
DataLookout
Menu

NCT07892027

Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Minor Start date changed from estimate of Nov 1, 2026 to Nov 10, 2026
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Occurrence of chimeric antigen receptor therapy (CAR-T)-associated neurotoxicity (immune effector cell associated neurotoxicity syndrome [ICANS])
Timeframe: Up to CAR-T day +28

Secondary (5)

Occurrence of severe CAR-T-associated neurotoxicity (ICANS of grade 3 or greater)
Occurrence of severe cytokine release syndrome (cytokine release syndrome [CRS] of grade 3 or greater)
Occurrence of adverse events related to natalizumab
Occurrence of complete response or partial response
Occurrence of serious adverse events related to natalizumab

Arms and interventions

Supportive care (SOC conditioning & CAR-T, natalizumab)Experimental

Patients receive SOC conditioning therapy consisting of fludarabine IV and cyclophosphamide IV on days -4 and -3. Patients then receive natalizumab IV over 1 hour on day -1, followed by SOC CAR T-cell therapy with axicabtagene ciloleucel or brexucabtagene autoleucel on day 0. Patients also undergo PET/CT and blood sample collection throughout the study.

Biologicals: Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, Natalizumab

Procedures: Biospecimen Collection, Computed Tomography, Positron Emission Tomography

Drugs: Cyclophosphamide, Fludarabine

Sites

1 site in 1 country

  • University of Michigan Rogel Cancer CenterAnn Arbor, Michigan, United States